| NDC包装代码 | 产品NDC | 产品类型 | 商品名 | 通用名 | 剂型 | 给药途径 | 上市日期 | 结束日期 | 市场类别 | 申请号 | 标签持有者 | 活性成分 | 规格 | 包装描述 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71777-392-01 | 71777-392 | HUMAN PRESCRIPTION DRUG | VITRAKVI | LAROTRECTINIB | SOLUTION | ORAL | 20181126 | N/A | NDA | NDA211710 | Loxo Oncology, Inc. | LAROTRECTINIB | 20 mg/mL | 100 mL in 1 BOTTLE (71777-392-01) |
| 50419-392-01 | 50419-392 | HUMAN PRESCRIPTION DRUG | VITRAKVI | LAROTRECTINIB | SOLUTION, CONCENTRATE | OROPHARYNGEAL | 20190726 | N/A | NDA | NDA211710 | Bayer HealthCare Pharmaceuticals Inc. | LAROTRECTINIB | 20 mg/mL | 100 mL in 1 BOTTLE (50419-392-01) |
| 50419-393-03 | 50419-393 | HUMAN PRESCRIPTION DRUG | VITRAKVI | LAROTRECTINIB | SOLUTION, CONCENTRATE | OROPHARYNGEAL | 20221206 | N/A | NDA | NDA211710 | Bayer HealthCare Pharmaceuticals Inc. | LAROTRECTINIB | 20 mg/mL | 2 BOTTLE in 1 CARTON (50419-393-03) / 50 mL in 1 BOTTLE (50419-393-02) |